GlassScriptPhysician profile
Brandy M Mcdonald
NPI 1871166843
$7,835.56
in general payments reported to CMS, 2019-2025
21 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $1,688 · 2023: $1,990 · 2024: $1,610 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,827 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,827.16 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,268.10 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,013.85 | 2021-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $889.84 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $857.84 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $839.39 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $721.75 | 2023-2025 | Auvelity |
| Abbvie INC. | $707.96 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $418.55 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $367.68 | 2021-2024 | Lybalvi, Aristada |
| Lundbeck LLC | $178.75 | 2022-2025 | Rexulti |
| Indivior INC. | $146.18 | 2021-2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $94.62 | 2022 | |
| Sunovion Pharmaceuticals INC. | $80.76 | 2022 | |
| Corium, LLC | $72.23 | 2022 | |
| Vanda Pharmaceuticals INC. | $67.02 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $43.20 | 2022-2023 | Secuado |
| Corcept Therapeutics | $17.50 | 2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $16.20 | 2025 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $15.55 | 2025 | |
| Ironshore Pharmaceuticals INC. | $13.63 | 2024 | |
| Phathom Pharmaceuticals, INC. | $4.96 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.